Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2017 | Combining a PARP and PD-L1 inhibitor to treat prostate cancer

Ravi A. Madan, MD, from the National Cancer Institute, Bethesda, MD, talks to us about current research on PARP inhibitors for the treatment of prostate cancer, presented at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL. He details his team’s current investigation on the combination of a PARP inhibitor, olaparib, and a PD-L1 inhibitor, durvalumab, in the treatment of metastatic castration-resistant prostate cancer and notes that these drugs may have a synergistic effect, although this requires further studies and analyses.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.